Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Share-based Compensation (2016 - 2025)

Marimed (MRMD) has disclosed Share-based Compensation for 10 consecutive years, with $382000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation rose 36.43% to $382000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.8 million, a 77.19% increase, with the full-year FY2024 number at $1.0 million, up 2.94% from a year prior.
  • Share-based Compensation was $382000.0 for Q3 2025 at Marimed, down from $549000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $5.6 million in Q3 2021 to a low of -$58000.0 in Q4 2022.
  • A 5-year average of $967812.5 and a median of $296500.0 in 2023 define the central range for Share-based Compensation.
  • Biggest YoY gain for Share-based Compensation was 477.59% in 2023; the steepest drop was 91.58% in 2023.
  • Marimed's Share-based Compensation stood at $5.6 million in 2021, then plummeted by 101.04% to -$58000.0 in 2022, then soared by 477.59% to $219000.0 in 2023, then rose by 26.94% to $278000.0 in 2024, then skyrocketed by 37.41% to $382000.0 in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Share-based Compensation are $382000.0 (Q3 2025), $549000.0 (Q2 2025), and $547000.0 (Q1 2025).